Início/BDX

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze BDX in workspace
BDXNYSE/health care

Becton, Dickinson and Company

$153.83Up+1,89 (+1,24%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Becton, Dickinson and Company operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Открытие
152,56
Максимум
154,93
Минимум
152,00
Капитализация
42,39 млрд
P/E
26.85
Максимум за 52 недели
--
Дивиденд
2.760%
Квартальный дивиденд
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. The base case remains conditional on separation complexity staying manageable.
Bull case
A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. New pharmacy automation, microbiology and interventional products can improve mix and customer workflows. A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.
Bear case
Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits. Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs. Provider labor and capital constraints can delay equipment upgrades and pressure pricing.
Thesis invalidation
Reassess the thesis if carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits.

Key catalysts

  • Recurring clinical supplies

    A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies.

  • Innovation pipeline

    New pharmacy automation, microbiology and interventional products can improve mix and customer workflows.

  • Portfolio separation

    A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

Principal risks

  • Separation complexity

    Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits.

  • Quality and regulatory risk

    Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs.

  • Hospital budget pressure

    Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

Latest earnings research

FY2026 Q2

BD's fiscal second-quarter 2026 update reflected demand across medication delivery, diagnostics and interventional products while the company continued portfolio-separation work and productivity initiatives.

Valuation interpretation

  • Recurring consumables support defensiveness, but the quality discount narrows only with consistent execution and product reliability.
  • Separation value should be assessed net of stranded costs, transition spending and the loss of diversification.

Peer research

ABTBSXISRG

Recent news

Trefis · 5 дней назад

The Wide Chasm Priced Into Boston Scientific Stock

Simply Wall St. · 5 дней назад

Becton Dickinson (BDX) Stock Trades At A Discount On Cash Flow And Earnings

Simply Wall St. · 5 дней назад

Becton Dickinson (BDX) Joins New Russell Indexes, Is The Stock Below Fair Value?

Zacks · 5 дней назад

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Motley Fool · 6 дней назад

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Trefis · 7 дней назад

How To Target A 10% Yield While Catching The BSX Stock Knife?

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
BD Reports Second Quarter Fiscal 2026 Financial ResultsBecton, Dickinson and Company · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 07/05/2026, 00:00:00

Open original source
Becton, Dickinson and Company Investor RelationsBecton, Dickinson and Company · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
BD SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 07/05/2026, 00:00:00

Open original source

Continue in the research workspace

Keep BDX in context, run a multi-agent analysis, and monitor thesis changes.

Analyze BDX free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.